INTENSITY THERAPEUTICS (INTS) Stock News

Intensity Therapeutics (Nasdaq: INTS), a late-stage clinical biotech company specializing in intratumoral cancer therapies, will participate in the H.C. Wainwright 27th Annual Global Investment Conference from September 8-10, 2025.

CEO Lewis H. Bender will engage in a fireside chat with Dr. Swayampakula Ramakanth, Managing Director and Senior Healthcare Analyst at H.C. Wainwright. The discussion will be available on-demand for registered conference attendees starting September 5, 2025, at 7:00 AM ET.

Intensity Therapeutics (Nasdaq: INTS), a late-stage clinical biotech company, has successfully regained compliance with Nasdaq's minimum Stockholders' Equity Requirement. The company confirmed having at least $2.5 million in stockholders' equity as of June 30, 2025, following successful fundraising efforts through July 2025.

Intensity, which focuses on developing novel intratumoral cancer therapies using its proprietary non-covalent conjugation technology, received confirmation from Nasdaq's Listing Qualifications Staff on August 8, 2025. CEO Lewis H. Bender stated that the company now projects having sufficient cash to fund operations into the second half of 2026.

Intensity Therapeutics (NASDAQ:INTS) reported Q2 2025 financial results and provided updates on its clinical trials. The company successfully raised over $11.3 million since Q2 2025, extending its cash runway into H2 2026. The INVINCIBLE-4 Study, testing INT230-6 in triple-negative breast cancer, showed promising early results with high tumor necrosis achieved in 8 days.

The company's Phase 3 INVINCIBLE-3 Study for soft tissue sarcoma has temporarily paused new enrollments due to previous funding constraints, though existing patients continue treatment. Q2 financial results showed reduced losses, with net loss decreasing to $2.5 million from $5.0 million year-over-year. R&D expenses decreased to $1.5 million from $3.6 million, while G&A expenses reduced to $1.2 million from $1.5 million.

Intensity Therapeutics (Nasdaq: INTS), a late-stage clinical biotech company, has successfully raised $6.6 million in gross proceeds ($6.3 million net) through its At-the-Market (ATM) offering in July 2025. The company sold 19.9 million shares at an average price of $0.3323 per share, which was notably 10% higher than its June 2025 public offering price.

The funding extends Intensity's cash runway into the second half of 2026, supporting the advancement of its clinical trials for novel intratumoral cancer therapies. Following the ATM sales, the company's total outstanding common stock reached 46 million shares as of July 31, 2025.

Intensity Therapeutics (Nasdaq: INTS) has announced significant preclinical results for its drug candidate INT230-6 in treating Malignant Peripheral Nerve Sheath Tumors (MPNST). The study, conducted at Johns Hopkins University's Staedtke-Bai laboratory, demonstrated a 100% complete response rate in murine models after 21 days of treatment.

The research involved two groups of test subjects (n=5 each), with the INT230-6 treatment group achieving complete responses while the control group's tumors continued to grow. This marks the first time INT230-6 has been tested in neurological-specific tumors, with researchers noting that no other small molecule drug has achieved such results in their lab previously.

The company plans to conduct additional preclinical research with the Staedtke-Bai laboratory to explore INT230-6's potential in other neurological cancer models.

Intensity Therapeutics (NASDAQ: INTS) has announced the pricing of its public offering of 6,675,000 common stock shares at $0.30 per share, aiming to raise gross proceeds of $2,002,500 before deductions. The company granted underwriters a 45-day option to purchase up to 1,001,250 additional shares. The offering is expected to close on June 13, 2025. Proceeds will fund patient enrollment and data readout for the INVINCIBLE-4 Study, support existing patients in the INVINCIBLE-3 Study, and provide working capital. ThinkEquity serves as the sole book-running manager. The offering is made through a shelf registration statement on Form S-3 filed with the SEC.

Intensity Therapeutics (NASDAQ: INTS), a late-stage biotech company developing novel intratumoral cancer therapies, has announced a proposed public offering of common stock. ThinkEquity will serve as the sole book-running manager. The proceeds will fund patient enrollment and data readout for the INVINCIBLE-4 Study, support existing patients in the INVINCIBLE-3 Study, and provide working capital. The offering will be made through a shelf registration statement on Form S-3. Intensity's lead drug, INT230-6, has shown promising results in clinical trials, demonstrating ability to kill tumors and elicit immune responses within days of injection. The company has completed two clinical studies with over 200 patients and is currently conducting Phase 3 trials in soft tissue sarcoma and Phase 2 studies in triple-negative breast cancer.

Intensity Therapeutics (NASDAQ: INTS) reported promising initial results from its Phase 2 INVINCIBLE-4 study of INT230-6 in early-stage triple-negative breast cancer (TNBC). The first patients receiving INT230-6 showed high levels of tumor necrosis within 8 days, before starting standard-of-care (SOC) treatment. The randomized study compares two doses of INT230-6 followed by SOC immunochemotherapy versus SOC alone, with pathological complete response (pCR) as the primary endpoint. The trial, currently recruiting in Switzerland and France, aims to enroll 54 patients. The SOC regimen includes pembrolizumab, anthracyclines, carboplatin, cyclophosphamide, and paclitaxel. Early results show promising tumor necrosis and inflammation after INT230-6 treatment, which could be significant as TNBC patients with pCR have better survival outcomes, while currently about 40% of patients fail to achieve pCR.

Intensity Therapeutics (NASDAQ: INTS) announced that its Phase 3 INVINCIBLE-3 clinical trial of INT230-6 for treating metastatic soft tissue sarcomas will be presented at the ASCO 2025 Annual Meeting. The presentation will be delivered by Dr. Sant P. Chawla on May 31, 2025. INT230-6, an intratumoral therapy, has shown promising results in Phase 1/2 trials, demonstrating a 93% disease control rate and 21.3 months median overall survival in refractory metastatic sarcoma patients. The drug causes significant tumor necrosis and cyst formation with minimal adverse events. However, new enrollment for the Phase 3 study has been temporarily paused due to funding constraints, though treatment continues for currently enrolled patients.